You might be a candidate if you have: A history of heart attack or stroke Coronary artery disease Heart failure Multiple risk factors for cardiovascular disease Research suggests these medications may help reduce the risk of major adverse cardiovascular events, though studies specific to Mounjaros cardiovascular benefits are still ongoing
Bottom Line on Cost: For Cash-Pay Patients: Best value: Compounded semaglutide at $199/month Maximum results: Compounded tirzepatide at $349/month Avoid: Brand-name at $1,000+/month (unsustainable) With Good Insurance: Try savings cards: May get $25/month brand-name If high copays: Compounded may be cheaper Factor in: Total out-of-pocket including deductibles Plan for long-term treatment costsobesity is a chronic condition requiring sustained therapy
This is an intellectual property dispute, but it's also a patient safety issue : Novo and Lilly, the only FDA-approved sources for semaglutide and tirzepatide, have said that they are not supplying compounders, which leaves open questions about what IS in their products
Subsequently, further lawsuits of a similar nature were brought against Novo and Eli Lilly and in February 2024 an initial 55 claims were consolidated into a federal Multi District Litigation ( MDL ) in Pennsylvania covering the medications Ozempic, Wegovy, and Rybelsus, manufactured by Novo, and Trulicity and Mounjaro, manufactured by Eli Lilly
